Fianlimab  (Synonyms: REGN3767)

Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

LAG3/CD223

Fianlimab inhibits the interaction between LAG-3 and MHC II, blockes the binding of MHC II-positive human Raji B cells and murine A20 B cells to HEK293/hLAG-3 cells, with EC₅₀s of 4.2 nM and 7.1 nM, respectively^[2].
Fianlimab restores T cell activity (EC₅₀=4.7 nM), promotes the secretion of IFNγ, and enhances antitumor immune responses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fianlimab (5-25 mg/kg, ip, twice a week for 2 weeks) exhibits protective effect against MC38.Ova colon cancer, inhibits tumor growth with the combination of Cemiplimab (HY-P99203) in mouse models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3902  [NCBI]

P18627

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.46 kDa

2126132-98-5

Liquid

Colorless to light yellow

[Fianlimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometric analysis of 1X10⁵⁰ Jurkat cells with Fianlimab (HY-P99617, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Omid Hamid, et al. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.Meeting Abstract | 2021 ASCO Annual Meeting I.

  [2]. Burova E, et al., Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062.  [Content Brief]